Table 4.

Overall responses and abscopal effects per treatment group

ParametersIpilimumab + LPT (n = 45)Ipilimumab (n = 82) (67)aP
Best systemic response (all patients)
 Complete remission (CR)3 (6.7%)0
 Partial remission (PR)14 (31.1%)12 (17.9%)
 Stable disease (SD)9 (20.0%)14 (20.9%)
 Progressive disease (PD)19 (42.2%)41 (61.2%)
 Clinical benefit (CR + PR + SD)26 (57.7%)26 (38.8%)0.05 (CR+PR+SD vs. PD)
Abscopal effects (AE)b
 LPT (n = 19)AE: n = 4 (21%)n.a.
 LPT + CNS radiotherapy (n = 6)AE: n = 0n.a.
 CNS radiotherapy (n = 15)n.a.AE: n = 3 (20%)
  • NOTE: The best systemic response was evaluated and classified according to RECIST (version 1.1).

  • aIn the ipilimumab group, response data on 15 patients were unavailable. Therefore, the relative numbers for responses in this group were calculated for a total of 67 patients.

  • bThe occurrence of abscopal effects (AE) could be retrospectively analyzed from 40 patient records with appropriate available data.